<DOC>
	<DOCNO>NCT00237198</DOCNO>
	<brief_summary>- Safety efficacy letrozole 2.5 mg/day monotherapy second-line endocrine therapy postmenopausal patient advance breast cancer receive previous anti-estrogen treatment - To investigate change blood drug concentration blood hormone kinetics . - To investigate gene polymorphism CYP2A6 , enzyme involved metabolism letrozole</brief_summary>
	<brief_title>Study Safety Efficacy Letrozole Monotherapy Second-line Endocrine Therapy Postmenopausal Patients With Advanced Breast Cancer Who Received Previous Anti-estrogen Treatment</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Estrogen Receptor Modulators</mesh_term>
	<mesh_term>Estrogen Antagonists</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>Patients histologically cytologically document breast cancer Patients progressive breast cancer ( advanced breast cancer , locoregional recurrence operative , metastatic breast cancer ) Patients hormone receptor ( ER and/or PgR ) positive unknown . Postmenopausal patient age 20 79 year , inclusive Patients history adjuvant therapy advance breast cancer treat antiestrogens Patients document measurable evaluable lesion . Patients sufficient organ function evaluate safety Patients whose performance status ( PS ) 0ï½ž2 Patients diffuse lymphangitis carcinomatosa lung CNS involvement , liver metastasis occupy one third liver , inflammatory breast cancer Patients concurrent previous malignant disease ( exclude contralateral breast cancer , situ carcinoma cervix uterus , adequately treat basal squamous cell carcinoma skin ) Patients one follow sole manifestation disease : hilar enlargement , pleural effusion ascites Patients blastic bone metastasis mixed blastic lytic bone metastases site measurable evaluable lesion Patients serious current disease uncontrolled cardiac disease and/or uncontrolled diabetes mellitus medication ( include historical serious cardiac disease ) Patients adrenal insufficiency ( treat untreated ) Cushing 's syndrome Patients follow previous treatment 1 . Chemotherapy metastatic and/or locoregional recurrent disease 2 . Previous adjuvant endocrine therapy ovariectomy , antiestrogen treatment , LHRH analogues radiation castration 3 . Previous firstline endocrine therapy ( e.g. , aromatase inhibitor gastagens ) treatment metastatic and/or locoregional recurrent breast cancer antiestrogen LHRH analogues treatment 4 . Patients recover toxicity cause previous therapy 5 . For patient investigational drug , adequate washout period least 7 day case topical investigational drug least 30 day case systemic 6 . Previous bisphosphonate therapy start within 6 month without measurable evaluable lesion 7 . Patients stop treatment antiestrogen anticancer drug ( bisphosphonates ) start trial medication Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Aromatase inhibitor</keyword>
	<keyword>letrozole</keyword>
	<keyword>breast cancer</keyword>
</DOC>